Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genor Biopharma Holdings Limited (HK:6998)
:6998
6998 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.90 - HK$3.25
Previous CloseN/A
Volume193.50K
Average Volume (3M)264.77K
Market Cap
€995.25M
Enterprise Value-HK$517.24M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding520,358,900
10 Day Avg. Volume456,350
30 Day Avg. Volume264,767
Standard Deviation0.18
R-Squared0.25
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)245.14
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Genor Biopharma Holdings Limited News
PremiumCompany Announcements
Genor Biopharma Announces Major Acquisition and Corporate Changes
PremiumCompany Announcements
Genor Biopharma Announces Auditor Change Following EGM
PremiumCompany Announcements
Genor Biopharma Announces Auditor Change at Upcoming EGM
PremiumCompany Announcements
Genor Biopharma Extends Merger Deadlines and Enters New Development Agreement
PremiumCompany Announcements
Genor Biopharma Announces Register Closure Ahead of EGMPremiumCompany Announcements
Genor Biopharma Proposes Auditor Change from PwC to EY
PremiumCompany Announcements
Genor Biopharma Announces New Hong Kong Office Location---
6998 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was HK$0.90 and its highest was HK$3.25 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is €995.25M.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Mar 26, 2025 which is in 28 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Genor Biopharma Holdings Limited released its earnings results on Aug 28, 2024. The company reported -HK$0.267 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.267.
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 520,358,900 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Genor Biopharma Holdings Limited reported an EPS of -HK$0.267 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.083%.
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in HK:6998
---
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL mAb drug candidate.
---
Technical Analysis
Ping An Insurance Company of China
―
Wuxi Biologics (Cayman)
―
Kangji Medical Holdings Limited
―
Viva Biotech Holdings
―
CanSino Biologics, Inc. Class H
―
---